Mylan (MYL) Gets Favorable Verdict for Copaxone in the US

Posted February 01, 2017

After $1.28 actual earnings per share reported by Teva Pharmaceutical Industries Ltd (ADR) for the previous quarter, Wall Street now forecasts 8.59% EPS growth. The company beat the analyst EPS Estimate with the difference of $0.03.

Out of 22 analysts covering Teva Pharma (NYSE:TEVA), 10 rate it a "Buy", 0 "Sell", while 12 "Hold". Analysts mean target price for Teva Pharmaceutical Industries Limited (NYSE:TEVA) is $44.70 while their mean recommendation is 2.30 (1=Buy, 5=sell). EPS growth in past five years was -13.10% while EPS growth in next five years is projected to arrive at 0.60%. Comparatively, growth in the past five years was -0.84 percent (per annum). Teva Pharmaceutical Industries Limited stock trades in the range of $34.20 to $34.99 before the earnings release. 14 analysts projected on average Earnings. Norway Savings Bank acquired a new position in shares of Teva Pharmaceutical Industries Limited during the fourth quarter worth about $429,000.

For the Current Quarter, the growth estimate for Teva Pharmaceutical Industries Limited is 6.2%, while for the Next Quarter the stock growth estimate is -3.3%. The High end of the Estimate is $6.4 Billion, while the Low end of the Estimate is $5.46 Billion. However a year ago for the same quarter the company has reported $1.28 EPS.

When it comes to the Analysis of a Stock, Price Target plays a vital role. Mizuho reaffirmed a buy rating and set a $64.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Monday, September 26th. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)'s shares are now trading -43.50% away from the 52-week high price of $61.10 and +7.51% far from the 52-week low price of $32.11. The firm has a market cap of $35.04 billion, a P/E ratio of 20.08 and a beta of 0.65. The $65.33 average target is 97.37% above today's ($33.1) stock price. The Company Touched its 52-Week High on Feb 1, 2016 and 52-Week Low on Jan 23, 2017. The Motley Fool recommends Momenta Pharmaceuticals and Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has declined 30.97% since June 24, 2016 and is downtrending. The highest and lowest price target given by the brokerage firms to the equity are $114 and $66.9, respectively. Stock monthly performance is recorded as -1.63% while its performance in last 5 sessions is 1.72%. The stock tumbled -16.15 percent over the last 6 months. The companys revenue was up 15.3% compared to the same quarter a year ago. By watching how many shares are trading hands and looking for any changes in that activity, trading opportunities can be spotted along with a deeper understanding of the reliability of other indicators on the stock. The returns on investment very popular metric among passive investors, it stands at 5.70%.

The companies mentioned in this article are subjects of research reports issued recently by investment firms. For the current year the company's revenue estimates are $21.68B compared to low analyst estimates of $21.49B and high estimates of $21.83B according to the projection of 25 analysts.